

---

# Genetics and Pathogenesis of Feline Infectious Peritonitis Virus

Meredith A. Brown, Jennifer L. Troyer, Jill Pecon-Slattery, Melody E. Roelke, and Stephen J. O'Brien

Feline coronavirus (FCoV) is endemic in feral cat populations and cat colonies, frequently preceding outbreaks of fatal feline infectious peritonitis (FIP). FCoV exhibits 2 biotypes: the pathogenic disease and a benign infection with feline enteric coronavirus (FECV). Uncertainty remains regarding whether genetically distinctive avirulent and virulent forms coexist or whether an avirulent form mutates *in vivo*, causing FIP. To resolve these alternative hypotheses, we isolated viral sequences from FCoV-infected clinically healthy and sick cats (8 FIP cases and 48 FECV-asymptomatic animals); 735 sequences from 4 gene segments were generated and subjected to phylogenetic analyses. Viral sequences from healthy cats were distinct from sick cats on the basis of genetic distances observed in the membrane and nonstructural protein 7b genes. These data demonstrate distinctive circulating virulent and avirulent strains in natural populations. In addition, 5 membrane protein amino acid residues with functional potential differentiated healthy cats from cats with FIP. These findings may have potential as diagnostic markers for virulent FIP-associated FCoV.

**F**eline infectious peritonitis (FIP) is an uncommon, fatal, progressive, and immune-augmented disease of cats caused by feline coronavirus (FCoV) infection. Although FCoV is common in most domestic, feral, and nondomestic cat populations worldwide (seroprevalence 20%–100%), FIP will develop in <10% of FCoV seropositive cats (1–4). FIP tends to occur most frequently in cats <2 years of age or, less commonly, in geriatric cats (4,5). The clinical manifestations of FCoV infection can be either a pathogenic disease, FIP (cases infected with feline infectious perito-

nitic virus [FIPV]) and, more commonly, a benign, or mild enteric infection (feline enteric coronavirus [FECV] asymptomatic) (6,7). Specific genetic determinants of these clinical outcomes have yet to be discovered. There is no effective treatment, vaccine, or diagnostic protocol that can discriminate the avirulent FECV from FIPV.

FIP pathology is characterized typically by severe systemic inflammatory damage of serosal membranes and widespread pyogranulomatous lesions, which occurs in the lungs, liver, lymph tissue, and brain (8). Evidence suggests that the host immune system is crucial in this pathogenesis; profound T-cell depletion from the periphery and lymphatic tissues and changes in cytokine expression are observed in end-stage FIP (9,10). The clinical finding of hypergammaglobulinemia-associated FIP is indicative of virus-induced immune dysregulation (11).

Viral genetic determinants specifically associated with FIPV pathogenesis have yet to be discovered. An *in vivo* mutation transition hypothesis postulated that *de novo* virus mutation occurs *in vivo*, giving rise to virulence (12,13). The precise nature of the mutation responsible for pathogenesis has not been identified, although studies have suggested sequence differences in the spike protein (14), nonstructural protein (NSP) 7b, and NSP3c (13) as disease determinants. Together with *in vitro* studies describing the FIPV strains affinity for macrophages in contrast to FECV strains (15), the hypothesis was extended to propose that the enteric coronavirus (FECV) undergoes a mutational shift in the gastrointestinal system, thus allowing infection of macrophages, systemic dissemination, and fatal disease manifestation (12,13). However, attempts to use engineered chimeric viruses designed to identify the operative virulence determinants have been unsuccessful (16). Furthermore, circulating FCoVs found in different tissues of FCoV-infected asymptomatic cats were indistinguishable (17,18).

---

Author affiliations: National Cancer Institute, Frederick, Maryland, USA (M.A. Brown, J. Pecon-Slattery, S.J. O'Brien); and SAIC-Fredrick, Inc., Frederick (J.L. Troyer, M.E. Roelke)

DOI: 10.3201/eid1509.081573

The *in vivo* mutation hypothesis of FIPV pathogenesis is widely cited, although it has never been explicitly confirmed. Mutational transition of HIV-1 has been demonstrated in AIDS patients, in which mutation of envelope residues alters coreceptor use from CCR5 to CXCR4, a prelude to the collapse of the CD4-bearing lymphocyte population (19). Similarly, key amino acid changes in the porcine coronavirus spike gene lead to increased virulence in the coronavirus transmissible gastroenteritis virus, a fatal disease causing high rates of illness and death in young pigs (20–22).

An alternative circulating virulent-avirulent FCoV hypothesis of viral pathogenesis suggests that distinctive benign and pathogenic strains of FECV circulate in a population, and that the disease will develop only in those persons infected by the virulent strains. Dengue virus may offer an example because it has been shown that 4 distinctive viral strains circulate worldwide, and severe hemorrhagic fever develops in persons exposed sequentially to distinct strains (23). Zoonotic equine Venezuelan encephalitis virus also displays circulating virulent and avirulent strains, which through interaction with ecologic and epidemiologic factors, contribute to or constrain the disease incidence (24).

This study aimed to systematically test evolutionary predictions of the *in vivo* mutation hypothesis versus the circulating virulent/avirulent hypothesis in the pathogenicity of FIP in the cat. We developed a study of naturally occurring FECV and FIPV using molecular genetic tools by collecting samples from field cases of FIP (cases) and FECV-positive but asymptomatic cats (controls). Cases were infected with feline coronavirus (FCoV) and had the clinical disease of feline infectious peritonitis (FIP). Controls were also infected with FCoV, but were clinically asymptomatic (FECV-asymptomatic). The prediction was that phylogenetic analysis of viral gene sequences would demonstrate paraphyly for FIP case-cats and FECV-asymptomatic cats if the *in vivo* mutation hypothesis was supported, and monophyly of the 2 if the circulating virulent/avirulent hypothesis was supported (Figure 1). Additionally, we surveyed the viral genetic diversity and dynamics and determined genetic signatures associated with pathogenesis in FIP.

## Materials and Methods

### Sampling

A total of 56 live, euthanized, or recently deceased domestic cats were clinically examined and sampled in Maryland veterinary hospitals during 2004–2006 (online Appendix Table 1, available from [www.cdc.gov/EID/content/15/9/1445-appT1.htm](http://www.cdc.gov/EID/content/15/9/1445-appT1.htm)). Blood (3–6 mL) was collected routinely by venipuncture from manually restrained or anesthetized domestic cats. Feces were obtained from the




Figure 1. Alternative phylogenetic predictions of the *in vivo* mutation hypothesis versus the dual circulating virulent/avirulent hypothesis. A) The *in vivo* mutation transition hypothesis predicts paraphyly of feline infectious peritonitis (FIP) cases and feline enteric coronavirus (FECV) asymptomatic feline coronavirus (FCoV) isolates. B) The circulating virulent/avirulent strain hypothesis predicts reciprocal monophyly of FIPV-cases versus FECV asymptomatic. Numbers represent individual cat (or locale), which is either FIPV case (red) or FECV asymptomatic (blue). Evidence presented in this article supports the circulating dual virulent and avirulent strains.

rectum by cotton swab and frozen in 0.5 mL of phosphate-buffered saline. Cats from 1 (Weller Farm) of 6 farms were micro-chipped (AVID, Folsom, LA, USA) for identification for repeat sampling of individual cats. Samples were collected in full compliance with specific federal permits (Convention on International Trade in Endangered Species; Endangered and Threatened Species) issued to the National Cancer Institute by the US Fish and Wildlife Service of the Department of the Interior.

For euthanized and recently deceased cats, gross necropsy examination and sample collection were performed within 2 hours of death. Samples from liver, spleen, mesenteric lymph node, kidney, jejunum, and colon were taken, fixed in 10% buffered formalin, and routinely embedded in paraffin. Sections (5  $\mu$ m) were stained with hematoxylin and eosin (HE). Tissues were also flash frozen in liquid nitrogen ( $-220^{\circ}\text{C}$ ) for RNA extraction and stored at either  $-220^{\circ}\text{C}$  or  $-70^{\circ}\text{C}$ .

### Clinical Hematologic and Biochemical Analysis

For complete blood counts, fresh (<12 hours) whole-blood samples were assessed by Antech veterinary diagnostic laboratory by using an automated cell counter (Avid Cell-Dyn 3500; Abbott Laboratories, Abbott Park, IL, USA). Biochemical analysis (Hitachi 717 Clinical Chemistry Analyzer; Roche Diagnostics, Indianapolis, IN, USA) and ELISA for feline immunodeficiency virus (FIV; Petchek FIV ELISA, Idexx Laboratories, Westbrook, ME,

USA), and coronavirus (Virachek CV, Synbiotics Corp., San Diego, CA, USA) antibodies were also performed.

**Pathologic and Immunohistochemical Analysis**

HE-stained slides of spleen, liver, lymph node, intestine, and kidney sections were evaluated for evidence of granulomatous and pyogranulomatous lesions (National Cancer Institute Laboratory Animal Sciences Program, Frederick, MD, USA). Formalin-fixed sections (3 μm thick) were cut from paraffin blocks and placed on glass slides for immunohistochemical (IHC) testing, as previously described, with CoV p56, a cross-reacting antibody for the demonstration of feline coronavirus (FECV and FIPV biotypes) (9,10) (Washington Animal Disease Diagnostic Laboratory, Pullman, WA, USA) (Figure 2).

**RNA Extraction and Reverse Transcription**

RNA from 160 μL ascites fluid or frozen feces suspended 10% in phosphate-buffered saline was extracted by using the QIAamp virus RNA mini kit (QIAGEN, Valencia, CA, USA) following the manufacturer’s instructions. RNA from tissue was extracted from ≈60 mg of frozen liver, lung, spleen, colon, jejunum, or lymph node by using RNeasy (QIAGEN) following the manufacturer’s instructions. Extracted RNA was eluted in 35 μL of RNase-free water and stored at –70°C. cDNA was reverse transcribed using 9 μL of eluted RNA (10 pg–5 μg) in an initial 12-μL

reaction mixture containing 50 ng of random hexamers and 0.5 mmol/L of dNTPs. After incubation at 65°C for 5 min to denature the RNA, 10 mmol/L of dithiothreitol, 5× Synthesis Buffer, 40 U of RNaseOUT, and 15 units of ThermoScript RT were added on ice (Invitrogen, Carlsbad, CA, USA). Reaction mixtures were incubated in thermocycler at 25°C for 10 min, followed by 50°C for 30 min. cDNA was stored at –20°C.

**PCR**

Primers amplifying 7b (736 bp), membrane protein (575 bp), polymerase (386 bp), and spike-NSP3 (1,017 bp) (Figure 3) were designed based on available feline coronavirus sequence (1,12,13). PCR was performed by using 2 μL of cDNA in a 50-μL reaction containing 50 mmol/L KCl, 10 mmol/L Tris-HCl (pH 8.3), 1.5 mmol/L MgCl<sub>2</sub>, 0.25 mmol/L concentrations of dNTPs (dATP, dCTP, dGTP, and dTTP), 2 mmol/L concentrations of each primer, and 2.5 units of Platinum Taq DNA polymerase (Invitrogen). PCR was conducted on a geneAmp PCR system 9700 thermocycler (Applied Biosystems, Foster City, CA, USA) with the following touchdown conditions: 2 min at 94°C then a touchdown, always starting with 20 sec at 94°C, then 30 sec at 60°C (3 cycles), 58°C (5 cycles), 56°C (5 cycles), 54°C (5 cycles), 52°C (22 cycles), and then 1 min at 72°C for extension, and with a final extension at 72°C for 7 min and a hold at 4°C. PCR products were visualized by




Figure 2. A) Histopathologic and immunohistochemical (IHC) results from 23 necropsied cats positive for antibodies against feline coronavirus. Liver, lung, spleen, colon, jejunum, stomach, heart, kidney, lymph node were evaluated by IHC. Feline infectious peritonitis (FIP) cases are highlighted in gray. Pos, positive; Neg, negative; ND, not done. B) Representative tissues from cat no. FCA-4653, spleen (histopathologic) showing granuloma (arrow); magnification ×20. C) Representative tissues from cat no. FCA-4590, small intestine (IHC); magnification ×20. D) Red staining indicates binding of coronavirus antibody (CoV p56, arrow); magnification ×100.




Figure 3. A) Feline coronavirus genome indicating PCR products obtained (bars). Structural proteins are shaded in dark gray; nonstructural proteins are shaded in light gray. B) Forward and reverse primers used to amplify virus segments are listed in 5' → 3' orientation. The number of source cats and cloned sequences generated from feline infectious peritonitis (FIP) cases and feline enteric coronavirus (FECV) asymptomatic cats are presented. Pol, polymerase; NSP, nonstructural protein; FIPV, feline infectious peritonitis virus.

electrophoresis on a 1% agarose gel and primers and unincorporated dNTPs were removed by using Microcon YM (Millipore, Billerica, MA, USA).

### Cloning and Sequencing

Representative PCR products were cloned and sequenced (Figure 3, panel B). Cloning was performed by using a TOPO-TA cloning kit (Invitrogen) according to the manufacturer's instructions. Plasmid DNA was isolated from 1–47 clones from each reaction product (Agencourt CosMCPrep; Agencourt Bioscience Corporation, Beverly, MA, USA). The presence of the correct sized insert was verified by restriction enzyme digestion (*EcoRI*), and sequences were obtained from clones with the correct insert by using standard ABI BigDye terminator reactions (Applied Biosystems). Anticontamination measures were taken at all steps of reverse transcription–PCR (RT-PCR) amplification and post-PCR processing.

### Phylogenetic Analysis

Sequences from *pol 1a*, *spike-NSP3*, *membrane*, and *NSP7b* were analyzed separately. Nucleotide sequences were compiled and aligned for subsequent phylogenetic analysis by using ClustalX (25) and verified visually (26). Analyses involved producing a phylogenetic tree of viral gene sequences based upon the following approaches: minimum evolution, maximum parsimony, and maximum likelihood in PAUP (27). Modeltest was used to estimate the optimal model of sequence evolution, and these settings were incorporated into subsequent analyses (28). Minimum evolution trees were constructed from models of substitution specified by Modeltest, with starting trees obtained by neighbor joining followed by application of a tree-bisection-reconnection (TBR) branch-swapping algorithm during a heuristic search for the optimal tree. Maximum parsimony analysis employed a heuristic search of starting trees obtained by stepwise addition followed by TBR. Maximum-likelihood parameters specified by Modeltest selected the general time-reversible model of substitution, included empirical base frequencies, and estimated rate

matrix and corrected for among-site rate variation (gamma distribution). A bootstrap analysis using 1,000 iterations was performed for maximum parsimony and minimum evolution and 100 iterations by using the nearest neighbor interchange branch-swapping algorithm for maximum likelihood. Amino acid residue alignments were generated using MacClade 3.05 (26) and ClustalX ([www.softpedia.com/get/Science-CAD/Clustal-X.shtml](http://www.softpedia.com/get/Science-CAD/Clustal-X.shtml)).

Variable sites and parsimoniously informative sites were computed in MEGA version 3.0 (29). Pairwise comparisons of genetic distances were performed in PAUP and the mean and range of genetic distances were calculated in Excel (Microsoft, Redmond, WA, USA). The sequences of FCoV *pol 1a*, *membrane*, *NSP 7b*, and *spike-NSP3* were deposited in GenBank under accession nos. EU663755–EU664317.

### Results

During 2004–2006, fifty-six domestic cats with suspected FIP or exposure to infected FIP cats from Maryland farms and veterinary hospitals were sampled (online Appendix Table 1). All samples producing RT-PCR products were from cats positive for antibodies against FCoV (titers >25). Thirty-six sampled cats were from the Weller farm where several individual cats were sampled once per year for the 3-year study period. Healthy and recently deceased or euthanized cats were included from the Ambrose farm (n = 7), Palmer Veterinary Hospital (n = 3), Frederick County Animal Shelter (n = 7), Seymour farm (n = 1), and the New Market Animal Hospital (n = 2). Fca-4590 from the Weller farm is an important FIP case because samples were obtained on May 20, 2004, when the cat was clinically healthy (predisease) and again on December 22, 2004, when FIP developed in the cat and it died (postdisease).

Necropsies were performed on 23 cats that died or were euthanized due to suspected FIP. Most of the necropsied cats were FCoV antibody positive (online Appendix Table 1). Eight cats were classified as FIP cases based on histopathologic findings (Fca-4549, Fca-4566, Fca-4590, Fca-4618, Fca-4653, Fca-4662, Fca-4663, and Fca-4664)

(Figure 2; online Appendix Table 1). The presence of pyogranulomatous lesions at histology evaluation was sufficient for designation of an FIP case. Additionally, 5 of the 8 FIP cases were evaluated by IHC testing. Multiple tissues were positive by IHC in each of these cats. One cat (Fca-4561) was IHC positive only in the jejunum and negative by histopathologic analysis on all tissues, therefore it was classified as FECV asymptomatic. The FCoV-seropositive necropsied cats with no characteristic FIP histopathologic changes and IHC lesions were classified as FECV asymptomatic (online Appendix Table 1; Figure 2). Healthy cats were classified as FECV asymptomatic if they had normal results on physical examinations, were FCoV antibody positive (titer >25) but not lymphopenic (<1.5 cells/ $\mu$ L), or were monitored until 2007 and known to be free of FIP disease (online Appendix Table 1).

RT-PCR was attempted with 4 primer pairs designed from FCoV genes for all cats (Figure 3, panel B). Of the 82 samplings from 56 cats, 42 samplings amplified virus with at least 1 primer pair yielding a 51% rate of recovery of viral sequence (online Appendix Table 1). From 8 cats with clinical FIP and 23 FECV-asymptomatic cats, amplification from the 4 viral regions produced 735 cloned viral gene segments that resulted in 501 unique gene sequences (online Appendix Table 2, available from [www.cdc.gov/EID/content/15/9/1445-appT2.htm](http://www.cdc.gov/EID/content/15/9/1445-appT2.htm); Figure 3, panel B).

Phylogenetic analysis of the cloned virus sequences from 3 Maryland locales sampled during 2004–2006 showed specific patterns of viral dynamics. First, gene sequences from healthy cats infected with FECV displayed a monophyletic cluster pattern that was generally distinctive from cats diagnosed with FIP in the *membrane*, *NSP 7b*, and *spike-NSP3* gene segments (Figure 4). For example, every FCoV gene sequence for the membrane gene from FIP cases fell within a major cluster consisting of 3 principal clades (Figure 4). By contrast, 127/154 (82%) virus gene sequences from FECV-asymptomatic cats sorted in 2 separate clades that were distinct (100 bootstrap statistical support) from the viral gene sequences of FIP cases (Figure 4). Similar reciprocal monophyly of 140 *NSP7b* sequences was obtained for FIP cases versus FECV-asymptomatic cats (Figure 4). A consistent disease driven phylogeographic sorting was also observed for the 1,017-bp sequence spanning the *spike-NSP3* genes, albeit with less statistical resolution, likely because of evolutionary constraints on gene divergence in this region (Figure 4). Together the remarkable reciprocal monophyly in these 3 genes supports the predictions of the circulating virulent-avirulent strain hypothesis illustrated in Figure 1.

Samples from 1 cat, Fca-4590, were particularly informative. The virus was isolated from the cat predisease, and then again 7 months later postdisease. Fca-4590 was asymptomatic but infected with FECV in May 2004. FCoV

sampling from that month showed strong (high bootstrap) affiliation with the FECV-asymptomatic clades for the membrane and the *NSP7b* genes. However, virus isolated




Figure 4. Maximum-likelihood (ML) phylogenetic tree of unique sequences from 3 feline coronavirus (FCoV) genes, *membrane*, *NSP 7b*, and *spike-NSP3* (see Figure 3), showing monophyly correlating to disease status. Cloned sequences from feline infectious peritonitis (FIP) cases are shown in red, feline enteric coronavirus (FECV) asymptomatic cats are shown in blue, and FCoV virulent strain from Aju-92 (cheetah) is in green. Shown above are *membrane* 575-bp sequences (ML –ln L = 3086.20787 best tree found by maximum parsimony [MP] tree: length = 493, CI = 0.551724, RI = 0.0926505); additional sequences are shown in an online expanded version of this figure, available from [www.cdc.gov/EID/content/15/9/1445-F4.htm](http://www.cdc.gov/EID/content/15/9/1445-F4.htm). The number of FIP cases and FECV-asymptomatic cats and number of cloned sequences is indicated in parenthesis. Each sequence is labeled as follows: source farm (W, Weller Farm; F, Frederick Animal Shelter; S, Seymour Farm; M, Mount Airy Shelter; A, Ambrose Farm), 4-digit cat identification number, tissue source (fe, feces; af, ascites fluid; co, colon; li, liver; sp, spleen; in, intestine; je, jejunum; ln, lymph node), 2-digit year (eg., 04 = 2004), and number of clones for each sequence. Bootstrap values are shown (MP/minimum evolution/ML) above branches. Where ML tree was congruent with MP tree, branch lengths are indicated below branches; the number of homoplasies is in parenthesis after the branch length. Number of cats and number of clones assessed are listed in Figure 3, panel B. Virus sequence obtained from cat no. 4590 in May 2004 and at the time of death due to FIP in December 2004 is indicated by box. The 4590-transitional individual serial samples are indicated with open circles (first sample) and solid circles (second sample). Scale bar indicates substitutions/site.

7 months later in December 2004 after FIP developed in Fca-4590 fell within the FIP-case clades (also with high bootstrap), and was indistinguishable from FCoV isolated from other cats with FIP. This finding suggested that the pathogenic FIP-case type of FCoV infected this cat subsequent to its infection with an avirulent FECV and apparently replaced it.

Tissue-specific differentiation within each cat was minimal (Figure 4). By contrast, there were notable locale-specific distinctions within the sick and healthy cats (Figure 4). For example, the FECV strains in asymptomatic cats from the Weller household were associated together in a major FECV subclade; strains in cats from the Frederick Animal Shelter were classified in a different subclade, nested within the FECV-asymptomatic clade (Figure 4). The archival FCoV virulent strain (Aju-92), isolated from cheetahs in Oregon in 1982 (30), defined a phylogenetic lineage distinctive from the FIP and FECV-asymptomatic clades resolved in the Maryland domestic cats (Figure 4).

Nucleotide sequences of *membrane* and *NSP 7b* generated in this study were translated to amino acid sequences (online Appendix Figure 1, available from [www.cdc.gov/EID/content/15/9/1445-appF1.htm](http://www.cdc.gov/EID/content/15/9/1445-appF1.htm)). Relative to pathogenesis, 5 informative amino acid sites were found in the membrane protein at positions 108, 120, 138, 163, and 199 (based on reference sequence for TGEV GenBank no. NP058427) (22), giving rise to 6 composite genotypes potentially diagnostic of FIP cases versus FECV-asymptomatic cats (online Appendix Table 2). Among the 8 cats with FIP, 19 FECV-asymptomatic cats, and 1 cheetah with FIP, 6 composite genotypes were identified based on these 5 diagnostic sites (online Appendix Table 2).

All domestic cats with FIP diagnosed by pathologic or immunohistochemical changes displayed the amino acid signature of either YIVAL (I) or YIIAL (II); infected cats without clinical FIP had the HIIVI (III), HIIIVL (IV), HVI-AL (V), YVVAL (VI), or YIVAL (I) haplotype. No FIP cases had haplotype III, IV, V, or VI, whereas 3 FECV-asymptomatic cats carried the YIVAL signature found predominately in FIP cases (Fca-4594, 4624, and 4657; online Appendix Table 2). Of these, 2 cats (4624 and 4657) were euthanized at the time of sampling (all euthanized FECV-asymptomatic cats are highlighted in light green in online Appendix Table 2); therefore, whether clinical FIP would have later developed in these cats is unknown. The other exception, cat 4594, was sampled twice (in 2004 and again in 2006); the switch in genetic signature from YIVAL in 2004 to HIIVI in 2006 may indicate that this cat was able to clear a virulent FIPV strain after the 2004 sampling and become reinfected with an avirulent strain by 2006. Although a strong phylogenetic signal differentiating FIP cases from FECV-asymptomatic cats was seen in *NSP 7b* (Figure 4), no diagnostic amino acid changes specific to

FIP cases vs. FECV-asymptomatic controls were found in the *NSP 7b* nucleotide or amino acid alignments. In contrast to the monophyletic findings in the *membrane*, *NSP 7b*, and *spike-NSP3* genes, cloned viral sequences of *pol 1a*, were paraphyletic in terms of disease phenotype (online Appendix Figure 2, available from [www.cdc.gov/EID/content/15/9/1445-appF2.htm](http://www.cdc.gov/EID/content/15/9/1445-appF2.htm)).

## Discussion

Infection with FCoV is common in cats throughout the world, although in most cats the virus causes no clinical signs. However, in some cats, FCoV infection is associated with the development of the progressive and fatal disease manifestation of FIP. This disease is among the most serious viral infections in cats, not only because of its fatal nature, but also because of the difficulties in diagnosing FIP antemortem and controlling the spread of FCoV. We have presented a molecular virologic study of naturally occurring FCoV infection and phylogenetic analysis of the cloned virus sequences obtained from the *membrane*, *NSP 7b*, *spike-NSP3*, and *pol 1a* genes isolated from domestic cats located in Maryland households infected with FCoV during 2004–2006. We observed predominately monophyletic clustering of strains correlating with disease phenotype in *membrane* and *NSP 7b* genes consistent with the circulating virulent/avirulent strain hypothesis of FIP pathogenesis, which calls into question the in vivo mutation hypothesis.

The amino acid alignments presented in online Appendix Figure 1 clearly demonstrate that in the FIPV cases included in this study the genotypes correlated with disease phenotype are ancestrally derived and not the result of a few de novo mutations. Given the clear genetic differentiation between viruses from FIP cases and FECV asymptomatic cats in multiple gene segments, we infer that cats become reinfected with new strains of FCoV from external sources, rather than by in vivo mutations. Cats in our study were not co-infected with multiple strains of FECV and FIPV at the same time and were generally infected with one predominant virus strain. Two exceptions to this finding in our study were cats with cases of FIPV (Fca-4662 and 4664) that from which distinct gastrointestinal (feces or intestine) and systemic (liver and/or ascites fluid) viral isolates were obtained, which indicates that in vivo superinfection does occur (Figure 4; online Appendix Table 2).

A role of the membrane protein in FIP pathogenesis seems likely, given its known functions in other coronaviruses. The membrane protein is the most abundant structural protein with important functions in virus budding and with cell-mediated host immunity (31). The specific functions of the membrane protein amino acid sequences have been determined in severe acute respiratory syndrome (SARS)–CoV (32). Aligning the sequences from this study with SARS-CoV, the first diagnostic amino acid site 108

aligns to a site just upstream from the second transmembrane helix (online Appendix Figure 1). A tyrosine at position 108, which is found in all FIPV biotypes and shared among SARS-CoV, has a neutral polarity (in contrast to a histidine there, found in most FECV biotypes, which have a positive polarity) and may play a role in the stability of the virus within the membrane. Site 120 aligns within the third transmembrane helix, site 138 aligns just downstream to the transmembrane helix, site 163 aligns within the C-terminus, which projects inside the virus particle, and site 199, also within the C-terminus domain, aligns within a defined SARS-immunodominant epitope (32) (Figure 5).

The demonstration of 6 naturally occurring composite genotypes based on 5 variable sites in the membrane protein amino acid alignment that are highly correlative with disease phenotype (online Appendix Table 2) offers specific opportunities for developing diagnostics and for the preventive management of this disease. By extending this study to additional cat populations in disparate geographic locations, designing chimeric FCoV challenge experiments, and investigating host genetic correlations with pathogenesis, we will be able to further discern the causative factors in FIP pathogenesis. Fca-4594, which was infected with the disease-associated genotype composite without succumbing to FIP, suggests additional requirements for viral pathogenesis. As has been suggested in the outbreak of FIP in a colony of captive cheetahs (33), host immune genetics may play a role.

Both the viral strain and host immune genes contribute to disease progression and virus-related death, such as AIDS progression in HIV infection. With the recent publication of the full cat genome sequence (34) and the viral genotype composites described here, new genomic tools are now available to proceed with both viral and host genetic association studies in the pathogenesis in FCoV infection, a model for coronavirus infection in humans, such as SARS-CoV.

### Acknowledgments

We thank Linda Rawls, Beth Weller, and Frederick County Animal Shelter for help with sample collection; Bailey Kessing and Nicole Crumpler for sample database management; Dahlem

Smith for histopathologic evaluation; and James Evermann for immunohistochemical assistance.

This study was supported in part by the National Cancer Institute, National Institutes of Health, under contract N01-CO-12400; and the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.

Dr Brown completed this work while a member of the Laboratory of Genomic Diversity at the National Cancer Institute. Currently, she is a postdoctoral research fellow at University College Dublin Veterinary Sciences Centre, Ireland. Her research interests include infectious disease studies in the cat animal model.

### References

1. Addie DD. Clustering of feline coronaviruses in multicat households. *Vet J*. 2000;159:8–9. DOI: 10.1053/tvj.1999.0429
2. Addie DD, Jarrett O. A study of naturally occurring feline coronavirus infections in kittens. *Vet Rec*. 1992;130:133–7.
3. Kennedy M, Citino S, McNabb AH, Moffatt AS, Gertz K, Kania S. Detection of feline coronavirus in captive *Felidae* in the USA. *J Vet Diagn Invest*. 2002;14:520–2.
4. Pedersen NC. A review of feline infectious peritonitis virus infection: 1963–2008. *J Feline Med Surg*. 2009;11:225–58. DOI: 10.1016/j.jfms.2008.09.008
5. Foley JE, Poland A, Carlson J, Pedersen NC. Risk factors for feline infectious peritonitis among cats in multiple-cat environments with endemic feline enteric coronavirus. *J Am Vet Med Assoc*. 1997;210:1313–8.
6. Pedersen NC, Evermann JF, McKeirnan AJ, Ott RL. Pathogenicity studies of feline coronavirus isolates 79-1146 and 79-1683. *Am J Vet Res*. 1984;45:2580–5.
7. de Groot RJ. Feline infectious peritonitis. In: Siddell SG, editor. *The Coronaviridae*. New York: Plenum Press; 1995. p. 293–309.
8. Weiss RC, Scott FW. Pathogenesis of feline infectious peritonitis: nature and development of viremia. *Am J Vet Res*. 1981;42:382–90.
9. Kipar A, Kohler K, Leukert W, Reinacher M. A comparison of lymphatic tissues from cats with spontaneous feline infectious peritonitis (FIP), cats with FIP virus infection but no FIP, and cats with no infection. *J Comp Pathol*. 2001;125:182–91. DOI: 10.1053/jcpa.2001.0501
10. Kipar A, Meli ML, Failing K, Euler T, Gomes-Keller MA, Schwartz D, et al. Natural feline coronavirus infection: differences in cytokine patterns in association with the outcome of infection. *Vet Immunol Immunopathol*. 2006;112:141–55. DOI: 10.1016/j.vetimm.2006.02.004




Figure 5. Diagram of membrane protein containing 3 transmembrane helices, an external N terminus and an internal carboxy terminus. Approximate position of 5 variable diagnostic amino acid sites (see Table 2) as determined by sequence comparison to severe acute respiratory syndrome coronavirus (32). Amino acid residue, polarity, and hydrophobicity or hydrophilicity is stated.

11. Hunziker L, Recher M, Macpherson AJ, Ciurea A, Freigang S, Hengartner H, et al. Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections. *Nat Immunol.* 2003;4:343–9. DOI: 10.1038/ni911
12. Poland AM, Vennema H, Foley JE, Pedersen NC. Two related strains of feline infectious peritonitis virus isolated from immunocompromised cats infected with a feline enteric coronavirus. *J Clin Microbiol.* 1996;34:3180–4.
13. Vennema H, Poland A, Foley J, Pedersen NC. Feline infectious peritonitis viruses arise by mutation from endemic feline enteric coronaviruses. *Virology.* 1998;243:150–7. DOI: 10.1006/viro.1998.9045
14. Rottier PJ, Nakamura K, Schellen P, Volders H, Haijema BJ. Acquisition of macrophage tropism during the pathogenesis of feline infectious peritonitis is determined by mutations in the feline coronavirus spike protein. *J Virol.* 2005;79:14122–30. DOI: 10.1128/JVI.79.22.14122-14130.2005
15. Stoddart CA, Scott FW. Intrinsic resistance of feline peritoneal macrophages to coronavirus infection correlates with in vivo virulence. *J Virol.* 1989;63:436–40.
16. Haijema BJ, Volders H, Rottier PJ. Switching species tropism: an effective way to manipulate the feline coronavirus genome. *J Virol.* 2003;77:4528–38. DOI: 10.1128/JVI.77.8.4528-4538.2003
17. Can-Sahna K, Soydal Ataseven V, Pinar D, Oguzoglu TC. The detection of feline coronaviruses in blood samples from cats by mRNA RT-PCR. *J Feline Med Surg.* 2007;9:369–72. DOI: 10.1016/j.jfms.2007.03.002
18. Dye C, Siddell SG. Genomic RNA sequence of feline coronavirus strain FCov ClJe. *J Feline Med Surg.* 2007;9:202–13. DOI: 10.1016/j.jfms.2006.12.002
19. Hartley O, Klasse PJ, Sattentau QJ, Moore JP. V3: HIV's switch-hitter. *AIDS Res Hum Retroviruses.* 2005;21:171–89. DOI: 10.1089/aid.2005.21.171
20. Ballesteros ML, Sanchez CM, Enjuanes L. Two amino acid changes at the N-terminus of transmissible gastroenteritis coronavirus spike protein result in the loss of enteric tropism. *Virology.* 1997;227:378–88. DOI: 10.1006/viro.1996.8344
21. Saif LJA. K. Transmissible gastroenteritis virus and porcine respiratory coronavirus. In: Zimmerman JJ, editor. *Diseases of swine.* 9th ed. Ames (IA): Iowa State University Press; 2006. p. 489–516.
22. Sanchez CM, Izeta A, Sanchez-Morgado JM, Alonso S, Sola I, Balasch M, et al. Targeted recombination demonstrates that the spike gene of transmissible gastroenteritis coronavirus is a determinant of its enteric tropism and virulence. *J Virol.* 1999;73:7607–18.
23. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanaawathana S, Tangthawornchaikul N, Chairunsri A, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. *Nat Med.* 2003;9:921–7. DOI: 10.1038/nm887
24. Anishchenko M, Bowen RA, Paessler S, Austgen L, Greene IP, Weaver SC. Venezuelan encephalitis emergence mediated by a phylogenetically predicted viral mutation. *Proc Natl Acad Sci U S A.* 2006;103:4994–9. DOI: 10.1073/pnas.0509961103
25. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL\_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. *Nucleic Acids Res.* 1997;25:4876–82. DOI: 10.1093/nar/25.24.4876
26. Maddison DRaM. W.P. MacClade 3.05. Sunderland (MA): Sinauer; 1995.
27. Swofford DL. PAUP\*: Phylogenetic Analysis Using Parsimony (\*and other methods). Sunderland (MA): Sinauer; 2002.
28. Posada D, Crandall KA. MODELTEST: testing the model of DNA substitution. *Bioinformatics.* 1998;14:817–8. DOI: 10.1093/bioinformatics/14.9.817
29. Kumar S, Tamura K, Nei M. MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. *Brief Bioinform.* 2004;5:150–63. DOI: 10.1093/bib/5.2.150
30. Pearks Wilkerson AJ, Teeling EC, Troyer JL, Bar-Gal GK, Roelke M, Marker L, et al. Coronavirus outbreak in cheetahs: lessons for SARS. *Curr Biol.* 2004;14:R227–8. DOI: 10.1016/j.cub.2004.02.051
31. Rottier PJ. The coronavirus membrane glycoprotein. In: Siddell SG, editor. *The Coronaviridae.* New York: Plenum Press; 1995. p. 115–40.
32. He Y, Zhou Y, Siddiqui P, Niu J, Jiang S. Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. *J Clin Microbiol.* 2005;43:3718–26. DOI: 10.1128/JCM.43.8.3718-3726.2005
33. Heeney JL, Evermann JF, McKeirnan AJ, Marker-Kraus L, Roelke ME, Bush M, et al. Prevalence and implications of feline coronavirus infections of captive and free-ranging cheetahs (*Acinonyx jubatus*). *J Virol.* 1990;64:1964–72.
34. Pontius JU, Mullikin JC, Smith DR, Lindblad-Toh K, Gnerre S, Clamp M, et al. Initial sequence and comparative analysis of the cat genome. *Genome Res.* 2007;17:1675–89. DOI: 10.1101/gr.6380007

Address for correspondence: Meredith A. Brown, Laboratory of Genomic Diversity, National Cancer Institute, Frederick, MD 21702, USA; email: brownmer@gmail.com

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated.

# etymologia

## *Borna disease virus*

[bor'nə]

Borna disease virus was named after the town of Borna in Saxony, southeastern Germany, where in 1885 many horses in a German cavalry regiment died of a fatal neurologic disease. The ill horses exhibited abnormal behavior—running about excitedly, walking into walls, being unable to chew food. A similar disease had been observed in horses, sheep, and cattle for more than 100 years. The causative agent was later found to be a negative-stranded RNA virus, which may also be a human pathogen.

**Source:** Carabone KM. Borna disease virus and its role in neurobehavioral disease. Washington: ASM Press; 2002.





4590-04* (5)	2	<u>4590feFE12</u>	.	.	.	.	L	.	.	.	.	H	.	.	.	.	I	.	.	.	.	V	.	.	I
	3	<u>Z4590feDFE05</u>	.	.	.	.	L	.	.	.	.	C	.	.	.	.	H	.	.	.	.	I	.	.	I
4561-04 (9)	3	<u>H4561feFD08</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	1	<u>4561fe04FF01</u>	.	.	.	.	V	.	.	.	.	L	.	.	.	.	V	.	.	.	.	I	.	.	I
4582-04(3)	1	<u>H4582feFB10</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	2	<u>4582feFD10</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
4582-06(4)	4	<u>H458206FC11</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	A	.	.	I
4583-05(6)	6	<u>Q4583fe05FC07</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
4585-04(3)	1	<u>4585feFF11</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	2	<u>4585feFH11</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
4585-06(8)	5	<u>I458506FF02</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	3	<u>I458506FH02</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
4586-04(4)	2	<u>G4586feFA09</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	2	<u>G4586feFG09</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	T
	4	<u>H4588feFC03</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	2	<u>H4588feFF03</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
4588-04(6)	4	<u>H4588feFC03</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	2	<u>H4588feFF03</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
4591-04(2)	2	<u>4591feFD03</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
4591-05(3)	1	<u>4591fe05FA06</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
4592-05(3)	3	<u>4592fe05FH05</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
4593-05(7)	1	<u>G4593feFC01</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
4593-06(7)	1	<u>4593fe06FC03</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	1	<u>4593fe06FD03</u>	.	.	.	.	P	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	1	<u>4593fe06FG03</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	2	<u>4593fe06FE03</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	2	<u>4593fe06FB03</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
4594-04(6)	4	<u>4594feFD09</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	2	<u>4594feFC09</u>	.	.	.	.	R	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
4594-06(6)	4	<u>I459406FA01</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	2	<u>I459406FB01</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
4595--04(2)	1	<u>4595feFA02gr20</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
4597-06(6)	1	<u>H459706FB05</u>	.	.	.	.	V	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	3	<u>459706F04gr19</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	1	<u>4597fe06FA04</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	1	<u>4597fe06FD04</u>	.	.	.	.	V	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
4606-04(4)	1	<u>H4606feFA09</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	3	<u>H4606feFG09</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
4606-06(2)	1	<u>G460606FB11</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	1	<u>G460606FE11</u>	.	.	.	.	V	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
4624--05(6)	1	<u>H4624feFG04</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	3	<u>4624feFD02</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
4655-05(1)	1	<u>4655IIFC03</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
4656-05(10)	2	<u>4656feFA10</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I
	8	<u>G4656FA12</u>	.	.	.	.	L	.	.	.	.	.	.	.	.	.	V	.	.	.	.	I	.	.	I

4657-05(5)	1	H4657feFC01	. . . . . L . . . . .	. . . . . T . . . . . A . . . . .	. . . . . D . . . . .
	1	H4657feFA01	. . . . . L . . . . .	. . . . . A . . . . .	. . . . . D . . . . .
	1	4657feFC04	. . . . . L . . . . .	. . . . . A . R . . . . .	. . . . . D . . . . .
	1	H4657feFD01	. . . . . L . . . . .	. . . . . A . . . . .	. . . . . D . . . . .
	1	H4657feFE01	. . . . . L . . . . .	. . . . . M A . . . . .	. . . . . D . . . . .
4659-05(9)	4	4659feFB11	. . . . . L . . . . .	. . . . . V . . . . . I . . . . .	. . . . . D . . . . .
	1	4659feFE11	. . . . . L . . . . .	. . . . . V . . . . . I M . . . . .	. . . . . C . . . . .
	2	4659feFD11	. . . . . L . . . . .	. . . . . V . . . . . I . . . . .	. . . . . I . . . . .
	2	H4659feFD06	. . . . . L . . . . .	. . . . . V . . . . . I I . . . . .	. . . . . A . . . . .
Aju-92(8)	3	Haju92liFC12	. . . . . L . . V . .	. . . . . V . . . . .	. . . . . D . . . . .
	1	Haju92liFE12	. . . . . L . . V . .	. . . . . R . . V . .	. . . . . D . . . . .
	1	Baju92li2FH01	. . . . . L . . V . .	. . . . . V . . . . . F . . . . .	. . . . . D . . . . .
	1	Haju92liFA12	. . . . . L . . V . .	. . . . . V . . . . .	. . . . . R . . . . .
	1	Haju92liFB12	. . . . . L . . A . .	. . . . . V . . . . .	. . . . . D . . . . .
1	Baju92li2FB01	. . . . . L . . V . .	. . . . . V . . . . .	. . . . . D . . . . .	
SARS	SARS	N N F . . L V F W L W . F V - V .	R N T G . . . . . C I V M L S . . F L R . M . . . . . L - N L T I V T M L V I R . L G C K D . E T . . S Y		
MHV-1	MHV-1	S . . I V . I . . M . I C . - .	A N Y L . . V T I . S M I . . . . . I . G . . . . . L - C M T V . . I H T I R . L G F S D . . T K H C Y		
IBV-Beu	IBV-Beu	T . V I L . I V . . . I G V T P P N G G L V .	I T . F A S V G I . I . R . . . . . S V G I T Q Q C N E M V K N . W L C D . . D F . R I R		
BCV-K	BCV-K	S . . V . . I . . M . I . . - .	A N Y L . . V T I . A M I V . . I . G . . . . . L - C M . M . I H T I R . L G Y S D . . T K H F Y		
HCV-229E	HCV-229E	K . L F L . . V . . . . S . W N W D N F V A F F .	S . M V . A . F . R T F . A W . V . - . V Q T . Y Q . . . . . L . V H N . . T V . I S		
TGEV	TGEV	. . . V . . . . .	. . . I . . I . . I . . . . . - C . . . . . E . . . . . I . M D N . . L . .		
FIPV79-1146	FIPV79-1146	. . L V . . . . .	. . . . . V . . . . .	. . . . . - C . . . . .	





D4590feDC05	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	D T
D4590feDF05	. . . . .	N N	. . . . .	A H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	D T
D4590feDG05	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	D T
D4590feDA08	. . . . .	N N	. . . . .	G H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	D T
B4590feDE04	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	D T
D4590feDC03	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	T V I	. . . . .	H V	. . . . .	D T
D4590feDD09	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	D T
D4590feDG06	. . . . .	N N	. . . . .	H V	. . . . .	G S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	D T
D4590feDF08	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	D T
D4590feDF04	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	V H V	. . . . .	D T
D4590feDE03	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	D T
D4590feDC07	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	I	. . . . .	H V	. . . . .	D T
B4590feDA04	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	D T
S4581feDE10	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
S4581feDH10	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	L S D T
S4581feDC10	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
E458306DB04	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
E458306DE04	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V V	. . . . .	S D T
E458306DG04	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
E458306DD04	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	K H V V	. . . . .	S D T
E458306DC04	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V V	. . . . .	S D T
S4584feDD09	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	V H V	. . . . .	S D T
S4584feDB09	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	V H V	. . . . .	S D T
S4584feDG09	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	V H V	. . . . .	S D T
E4586feDF07	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
E4586feDE07	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
E4586feDD07	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
E4589feDF06	. . . . .	N N	. . . . .	H V	. . . . .	A S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	D T
E4591feDF12	. . . . .	S N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
E4591feDG12	. . . . .	M N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
S4591feDD06	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
4591feh11	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	D I	. . . . .	H V	. . . . .	S D T
4591feh7	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
W4591feDH06	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
W4591feDF06	. . . . .	N N	. . . . .	S H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T A
E4591feDB12	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
4591feh12	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T A
E4591feDE12	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
W4591feDB06	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	R H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
4591feh10	. . . . .	N N	. . . . .	H V	. . . . .	P S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
E4591feDC12	. . . . .	I N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
S4591feDG06	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
S4594fe06DD	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T P
S4594fe06DF	. . . . .	N N	. . . . .	H V	. . . . .	I S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
S4594fe06DB	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
S4594fe06DE	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	S H V	. . . . .	S D T
S4594feDC12	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T
S4595feDF11	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V T	. . . . .	H V	. . . . .	S D T N
E4595feDE01	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T N
E4595feDF01	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	A H V	. . . . .	S D T

S4595feDD11	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T	. . . . .
S4595feDE11	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	Q H	. . . . .	V I	. . . . .	H V	. . . . .	S D T	. . . . .
S4595feDH11	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T	. . . . . N
S4595feDG11	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V T	. . . . .	H V	. . . . .	S D T	. . . . .
S4597fe06DC	. . . . .	N	. . . . .	H V	. . . . .	S	. . . . .	L L	. . . . .	V I	. . . . .	H V	. . . . .		. . . . .
S4597fe06DG	. . . . .	I	. . . . .	H V	. . . . .	S	. . . . .	F	. . . . .	V I	. . . . .	H V	. . . . .		. . . . .
S4597fe06DA	. . . . .	N	. . . . .	H V	. . . . .	S	. . . . .	F	. . . . .	V I	. . . . .	H V	. . . . .		. . . . .
S4597fe06DF	. . . . .	N	. . . . .	H V	. . . . .	S	. . . . .	L	. . . . .	V I	. . . . .	H V	. . . . .		. . . . .
S4597fe06DD	. . . . .	N	. . . . .	H V	. . . . .	S	. . . . .	L	. . . . .	V I	. . . . .	H V	. . . . .		. . . . .
S4597fe06DE	. . . . .	N	. . . . .	H V	. . . . .	S	. . . . .	L	. . . . .	V I	. . . . .	H V	. . . . .		. . . . .
E460606DF09	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T	. . . . . H
E460606DC09	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T	. . . . . H
E460606DE09	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T	. . . . . H
E4609feDC02	. . . . .	H	. . . . .		. . . . .	S	. . . . .		. . . . .		. . . . .		. . . . .		. . . . .
E4609feDB02	. . . . .		. . . . .		. . . . .	S	. . . . .		. . . . .		. . . . .		. . . . .		. . . . .
E4609feDE02	. . . . .		. . . . .		. . . . .	S	. . . . .	V	. . . . .		. . . . .		. . . . .		. . . . .
E4609feDH02	. . . . .		. . . . .		. . . . .	S	. . . . .		. . . . .		. . . . .		. . . . .		. . . . .
E4609feDA02	. . . . .		. . . . .		. . . . .	S	. . . . .	V	. . . . .		. . . . .		. . . . .		. . . . . C
E4612feDA08	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T	. . . . . R
E4612feDB08	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T	. . . . .
E4612feDG08	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H	. . . . .	L	. . . . . S D T
E4612feDD08	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	T V I	. . . . .	H	. . . . .		. . . . . S D T
E4612feDC08	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T	. . . . .
E4612feDF08	. . . . .	N N	. . . . .	H V	. . . . .	S	. . . . .	H	. . . . .	V I	. . . . .	H V	. . . . .	S D T	. . . . .
S4624feDB05	. . . I D	H P	. . . . .	D I H	. . . . .	S	. . . . .	D	. . . . .		. . . . .	H V	. . . . .	Q Y Y	. . . . . A H
S4624feDF05	. . . I D	H P	. . . . .	D I H	. . . . .	S	. . . . .	D	. . . . .		. . . . .	H V	. . . . .	Q Y Y	. . . . . A H
S4624feDH05	. . . I D	H P	. . . . .	D I H	. . . . .	S	. . . . .	D	. . . . .		. . . . .	A H V	. . . . .	Q Y Y	. . . . . A H
S4656feDD07	. . . N	Y	. . . . .	H	. . . . .	D S	. . . . .	H	. . . . .	G	. . . . .	H V	. . . . .		. . . . . T H
E4656feDC10	. . . N	Y	. . . . .	H	. . . . .	D S	. . . . .	H	. . . . .	G	. . . . .	H V	. . . . .		. . . . . T H
E4656feDA10	. . . N	Y	. . . . .	H	. . . . .	D S	. . . . .	H	. . . . .	G	. . . . .	H V	. . . . .		. . . . . T H
S4656feDA07	. . . N	Y	. . . . .	H	. . . . .	D S	. . . . .	D	. . . . .	H	. . . . .	G	. . . . .		. . . . . T H
E4657feDA11	. . . D	Y	. . . . .	I H V F I V	. . . . .	S I	. . . . .	L E S	. . . . .	Y	. . . . .	H V	. . . . .	S Y T	. . . . . M H D
E4657feDE11	. . . D	Y	. . . . .	I H V F I V	. . . . .	S I	. . . . .	L E S	. . . . .	Y	. . . . .	H V	. . . . .	S Y T	. . . . . M H D
E4657feDB11	. . . D	Y	. . . . .	I H V F I V	. . . . .	S I	. . . . .	L E S	. . . . .	Y	. . . . .	H V	. . . . .	S	. . . . . T M H D
S4659feDG08	. . . N	Y	. . . . .	H	. . . . .	D S	. . . . .	H	. . . . .	D G	. . . . .	H V	. . . . .		. . . . . T H
FECVUCD	R . .	A A D	. . . . .	H	. . . . .	S	. . . . .	F	. . . . .	H	. . . . .	S	. . . . .	H V	. . . . . Q S T H M D
FIPVUCD1	. V	A A N	. . . . .	H	. . . . .	S	. . . . .	H	. . . . .		. . . . .	S	. . . . .	H V	. . . . . P Y S T H M D
FIPV791146	. . .	A N	. . . . .	D I H V	. . . . .	I	. . . . .	D	. . . . .		. . . . .	S	. . . . .	H V	. . . . . D D T H R D
FIPVUCD3	R . .	A A D	. . . . .	H	. . . . .	S	. . . . .	F	. . . . .	H D	. . . . .	S	. . . . .	H V	. . . . . Q S T H M D
Aaju92liDH1	1 T	A Y	. . . . .	N Y H S	. . . . .	I	. . . . .	D S I	. . . . .	S	. . . . .	S	. . . . .	I	. . . . . M V D T H N D
Aaju92liDC1	1 T	A Y	. . . . .	N Y H S	. . . . .	I	. . . . .	D S I	. . . . .	S	. . . . .	S	. . . . .	I Q	. . . . . M V D T H N D
Aaju92liDD1	1 T	A Y	. . . . .	N Y H S	. . . . .	I	. . . . .	D S I	. . . . .	S	. . . . .	S	. . . . .	I	. . . . . M V D T H N D
Aaju92liDF1	1 T	A Y	. . . . .	N Y H S	. . . . .	I	. . . . .	D S I	. . . . .	S	. . . . .	S	. . . . .	I G	. . . . . M V D T H N D

Appendix Table 1. Clinical, demographic, and FCoV viral RT-PCR success data from 56 domestic cats sampled in Maryland, USA, 2004–2006\*

Cat ID	Farm	Sex/age	FCoV gene sequences						
			2004	2005	2006	Status 2007	IHC/Histo	PE	FCoV
4549	Weller	M/1.5 y	M,7,P,3	–	–	D	Pos	–	Pos
4561	FCAC	F/3 y	M,P,3	–	–	E	Neg (pos SI)	WNL	Neg
4562	Palmer	M/1 y	–	–	–	E	Neg	WNL	Neg
4563	Palmer	M/1 y	–	–	–	E	Neg	WNL	Pos
4564	Palmer	M/1 y	–	–	–	E	Neg	WNL	Neg
4566	Weller	M/1.5 y	M,7,P,3	–	–	D	Pos	AB	Pos
4580	Weller	F/1 y	–	–	–	H	–	WNL	Pos
4581	Weller	F/1 y	7	–	–	H	–	WNL	Pos
4582	Weller	F/1 y	M	M	–	H	–	WNL	Pos
4583	Weller	M/1 y	–	M	–	H	–	WNL	–
4584	Weller	F/2 y	7	–	3	H	–	WNL	Pos
4585	Weller	M/1 y	M	–	M	H	–	WNL	Pos
4586	Weller	F/1 y	M,7,3	–	–	H	–	WNL	Pos
4587	Weller	M/1 y	–	–	–	H	–	WNL	Pos
4588	Weller	M/1 y	M	–	–	H	–	WNL	Pos
4589	Weller	M/1 y	M,7	–	–	H	–	WNL	Pos
4590	Weller	M/2 y	M,7	M,7,3	–	D	Pos	AB	Pos
4591	Weller	F/1 y	M,7,P	M	–	H	–	WNL	Pos
4592	Weller	F/1 y	–	M	–	H	–	WNL	Pos
4593	Weller	M/1 y	7,P	M	M	H	–	WNL	Pos
4594	Weller	F/1 y	M,7,P	–	M,7	H	–	WNL	Pos
4595	Weller	F/1 y	M,7,P,3	–	–	H	–	WNL	Pos
4596	Weller	F/1 y	–	–	–	H	–	AB	Pos
4597	Weller	F/1 y	P	–	M,7,3	H	–	WNL	Pos
4606	Weller	F/4 y	M	–	M,7	H	–	WNL	Pos
4607	Weller	M/3 y	–	–	–	H	–	WNL	Pos
4608	Weller	F/3 y	–	–	–	H	–	WNL	Neg
4609	Weller	F/1 y	7	–	–	H	–	AB	Pos
4611	Weller	M/7 y	–	–	–	H	–	WNL	Pos
4612	Weller	F/1 y	7,3	–	–	H	–	WNL	Pos
4613	Weller	F/4 y	–	–	–	H	–	WNL	Pos
4614	Weller	M/5 y	–	–	–	H	–	WNL	Pos
4615	Weller	F/7 y	–	–	–	H	–	WNL	Pos
4616	Weller	F/6 y	–	–	–	H	–	WNL	Pos
4618	Weller	M/1 y	M,7	–	–	D	Pos	AB	Pos
4620	Weller	M/6 y	–	–	–	D	Pancreatitis	AB	Neg
4623	Weller	UK/UK	–	–	–	D	Neg	AB	Neg
4624	Seymour	F/2y	–	M,P,3,7	–	E	Lymphoma	AB	–
4625	Weller	F/1 y	P	–	–	D	Lymphoma	AB	–
4626	Ambrose	F/11 y	–	–	–	H	–	WNL	–
4627	Ambrose	M/11 y	–	–	–	H	–	WNL	Pos
4628	Ambrose	F/7 y	–	–	–	H	–	WNL	Pos
4629	Ambrose	F/7 y	–	–	–	H	–	WNL	Pos
4630	Ambrose	M/4 y	–	–	–	H	–	WNL	Pos
4631	Ambrose	M/2 y	–	–	–	H	–	WNL	Pos
4653	Ambrose	F/4 y	–	–	M,7,P,3	D	Pos	AB	Pos
4654	NM	M/2 mo	–	–	–	D	SI enteritis	AB	Pos
4655	FCAC	F/2 mo	–	–	–	E	Neg	AB	Pos
4656	FCAC	M/6 wk	–	7,M,3	–	E	Neg	WNL	–
4657	FCAC	M/6 wk	–	M,7	–	E	Neg	WNL	Pos
4658	FCAC	M/3 wk	–	–	–	E	Neg	WNL	Pos
4659	FCAC	M/6 wk	–	M,7,3	–	E	Neg	WNL	Pos
4660	FCAC	M/8 wk	–	–	–	E	Neg	WNL	Pos
4662	Weller	M/4 mo	–	–	M,7,P,3	E	Pos	–	–
4663	Weller	F/4 mo	–	–	M,7,P,3	E	Pos	–	–
4664	NM	M/6 mo	–	–	M,7,3	E	Pos	–	–

\*FCoV, feline coronavirus; RT-PCR, reverse transcription–PCR; ID, identification number; IHC, immunohistochemical; PE, physical exam; M, membrane; D, dead; Pos, positive; FCAC, Frederick County Animal Shelter; E, euthanized; Neg, negative; SI, small intestine; WNL, within normal limits; AB, abnormal pathology; H, healthy; UK, unknown; NM, New Market Animal Shelter. Shaded cells in left column represent 8 FIP cases.



Appendix Table 2. Genotype composites of 8 FIPV and 19 FECV domestic cats in Maryland, USA, sampled 25 times at 5 variable amino acids in the FCoV membrane protein\*

Cloned NT sequences	Amino acid sequences	FCA cat ID†	Source‡	108§	120§	138§	163§	199§	Year	Farm	Genotype
17	10	4549	AF, LI, LN, CO	Y	I	V	A	L	2004	Weller	I
18	7	4566	JE	–	–	–	–	–	2004	Weller	I
17	12	4618	LI, LN, FE	–	–	–	–	–	2004	Weller	I
3	3	4662	FE	–	–	–	–	–	2006	Weller	I
13	5	4663	FE, LI	–	–	–	–	–	2006	Weller	I
3	2	4664	JE	–	–	–	–	–	2006	MA	I
12	1	4590	SI	–	–	–	–	–	2004 Dec	Weller	I
6	3	4653	SP, LI	–	–	I	–	–	2004	Ambrose	II
3	3	4662	LI	–	–	I	–	–	2006	Weller	II
11	7	4664	AF, LI	–	–	I	–	–	2006	MA	II
5	2	4590	FE	H	–	I	V	I	2004 May	Weller	III
13	2	4582	FE	H	–	I	V	I	2004	Weller	III
6	2	4583	FE	H	–	I	V	I	2005	Weller	III
3	6	4585	FE	H	–	I	V	I	2004	Weller	III
9	3	4585-06	FE	H	–	I	V	I	2006	Weller	III
2	3	4586	FE	H	–	I	V	I	2004	Weller	III
5	3	4588	FE	H	–	I	V	I	2004	Weller	III
15	1	4591	FE	H	–	I	V	I	2004	Weller	III
6	2	4594-06	FE	H	–	I	V	I	2006	Weller	III
2	1	4595	FE	H	–	I	V	I	2004	Weller	III
6	4	4597	FE	H	–	I	V	I	2006	Weller	III
3	2	4606	FE	H	–	I	V	I	2004	Weller	III
1	1	4593	FE	H	–	I	V	–	2004	Weller	IV
2	2	4606-06	FE	–	V	I	–	–	2006	Weller	V
9	4	4561	FE	–	V	I	–	–	2004	FCAC	V
6	2	4582-06	FE	–	V	I	–	–	2006	Weller	V
3	1	4591-05	FE	–	V	I	–	–	2005	Weller	V
3	2	4592	FE	–	V	I	–	–	2005	Weller	V
7	6	4593-06	FE	–	V	I	–	–	2006	Weller	V
10	3	4656	FE	–	V	I	–	–	2005	FCAC	V
9	9	4659	FE	–	V	I	–	–	2005	FCAC	V
1	1	4655	FE	–	V	–	–	–	2005	FCAC	VI
6	2	4594	FE	–	–	–	–	–	2004	Weller	VI
6	4	4624	FE	–	–	–	–	–	2005	Seymour	VI
6	5	4657	FE	–	–	–	–	–	2005	FCAC	VI
8	8	Aju-92	LI	–	V	–	–	–	1982	WSP	VI
–	–	FIPV79-1146	GenBank	–	V	–	–	–	1991	Wash	VI
–	–	FIPV79-1683	GenBank	–	V	–	–	–	1991	Wash	V
–	–	SARS	GenBank	–	–	F	L	C	2003	–	–
–	–	MHV-1	GenBank	–	–	I	M	F	2007	–	–
–	–	IBV-Beu	GenBank	P	–	I	T	C	2001	–	–
–	–	BCV-K	GenBank	–	–	I	M	Y	2007	–	–
–	–	HCV-229E	GenBank	W	F	F	V	V	1990	–	–
–	–	TGEV	GenBank	–	–	I	–	M	1986	–	–

\*FIPV, feline infectious peritonitis virus; FECV, chronic feline enteric infection; FCoV, feline coronavirus; NT, nucleotide; AF, ascites fluid; LI, liver; LN, lymph node; CO, colon; JE, jejunum; FE, feces; SI, small intestine; SP, spleen; FCAC, Frederick County Animal Shelter.

†No. corresponding unique amino acid sequences. Pink shading, FIPV cats; green shading, FECV cats; blue shading, FCoV-infected healthy cats; gold shading, FCoV-Aju cat.

‡Identification number (see [Appendix Table 1](#)).

§Membrane protein amino acid residues tyrosine (Y), isoleucine (I), valine (V), alanine (A), leucine (L), histidine (H) (GenBank reference sequence number P04135). –, identical amino acid residue as reference (first line); grey shading indicates different amino acid. Genotype composite of FCoV-Aju reported here; cell line (6) and reference sequences for SARS-CoV, MHV-1, IBV-Beu, BVC-K, HCoV-229E, TGEV-Purdue, and FCoV 79-1146 (GenBank accession numbers P59596, AB587268, P69602, BAF75636, P15422, PO4135, and P25878, respectively) are also shown.

Appendix Table 3. Additional clinical data from 56 domestic cats sampled in Maryland, USA, 2004–2006\*

Cat ID	Name	Hem	RBC	WBC	Lymph	Neut	Bands	Pro	Glo	Bili	Toxo/ FeLV	FIV
FCA-4549	Hank	41.1	8.55	4.2	210	3,864	84	–	–	–	Toxo 1:128	Neg
FCA-4561	PregnantF	24.9	5.79	5.1	4,539	357	0	–	–	–	–	Neg
FCA-4562	Bryan	0.3	0.23	8.3	415	387	0	7.4	3.6	0.3	–	Neg
FCA-4563	Dreamcylcle	27.3	6.32	9.4	1,222	7,802	0	7.7	4.4	0.1	Neg	Neg
FCA-4564	Michael	7.1	0.24	6.5	975	810	0	7.2	3.6	0.1	Neg	Neg
FCA-4566	Ace	21.3	4.68	5.9	295	5,192	0	–	–	–	–	–
FCA-4580	Phoebe	33.6	7.61	11.2	5,936	3,920	0	–	–	–	–	–
FCA-4581	Palmer	42.7	9.89	13.8	4,002	8,142	0	–	–	–	–	–
FCA-4582	Ying	40.7	8.6	12.2	5,490	4,880	0	–	–	–	–	–
FCA-4583	Yang	–	–	–	–	–	–	–	–	–	–	–
FCA-4584	Sydney	28.9	6.12	8.2	1,476	6,150	0	–	–	–	–	–
FCA-4585	Swain	–	–	–	–	–	–	–	–	–	–	–
FCA-4586	Josie	36.6	8.05	11	2,970	6,050	0	–	–	–	–	–
FCA-4587	Mo jo	41.3	8.33	11.8	3,068	7,080	0	–	–	–	–	–
FCA-4588	Simpson	36.5	8.36	7.7	2,079	5,005	0	–	–	–	–	–
FCA-4589	Ty	41.3	9.58	10.3	3,193	5,871	0	–	–	–	–	–
FCA-4590	Diesel	–	–	–	–	–	–	–	–	–	Neg/neg	Neg
FCA-4591	Chenille	38	8.39	18	9,180	7,200	0	–	–	–	–	–
FCA-4592	Kerrigan	39.8	8.85	19.4	9,312	8,730	0	–	–	–	–	–
FCA-4593	Leroy	39.2	8.75	11.4	2,508	7,524	0	–	–	–	–	–
FCA-4594	Ursa	–	–	–	–	–	–	–	–	–	–	–
FCA-4595	Snuffy	–	–	–	–	–	–	–	–	–	–	–
FCA-4596	Teva	–	–	–	–	–	–	–	–	–	–	–
FCA-4597	Bings	27.9	5.95	14.7	2,058	10,731	0	–	–	–	–	–
FCA-4606	Elsa	34.1	7.4	15.4	3,850	9,856	0	–	–	–	–	–
FCA-4607	BamBam	32.3	7.54	12.4	3,720	8,556	0	–	–	–	–	–
FCA-4608	Layla	32.8	7.68	14.9	4,619	8,940	–	–	–	–	–	–
FCA-4609	Queenie	33.7	6.61	6.9	2,208	3,933	0	–	–	–	–	–
FCA-4611	Cheeks	35.4	7.61	14.6	3,212	10,366	0	–	–	–	–	–
FCA-4612	Rocket	29.6	6.12	10.1	2,323	6,868	0	–	–	–	–	–
FCA-4613	Jasmine	40	7.83	11.2	2,240	7,280	0	–	–	–	–	–
FCA-4614	BoBo	37	9.39	7	1,260	5,180	0	–	–	–	–	–
FCA-4615	Patches	30.4	6.64	35	1,750	29,750	1,400	–	–	–	–	–
FCA-4616	Isis	36.1	6.54	15.2	4,104	8,816	0	–	–	–	–	–
FCA-4618	Elliot	–	–	–	–	–	–	–	–	–	–	–
FCA-4620	Tony	–	–	–	–	–	–	–	–	–	Neg/neg	Neg
FCA-4623	KofBings	–	–	–	–	–	–	–	–	–	–	–
FCA-4624	Zoe	30.5	6.46	26	16,900	6,760	260	6.8	3.4	0.1	–	–
FCA-4625	Goldie	–	–	–	–	–	–	–	–	–	FeLV neg	Neg
FCA-4626	Saddie	–	–	–	–	–	–	–	–	–	FeLV pos	Neg
FCA-4627	Sassy	31.6	7.93	8	6,000	1,600	0	–	–	–	–	–
FCA-4628	Rosie	qns	qns	8	2,560	4,880	0	7.5	5.1	0.3	Neg/neg	Neg
FCA-4629	Lilly	18.8	4.93	7.4	962	5,994	0	–	–	–	Neg/neg	Neg
FCA-4630	Rudy	32.9	7.2	10.3	6,901	2,781	0	7.2	4.2	0.3	Neg/neg	Neg
FCA-4631	Boy	qns	qns	5.6	3,136	2,184	0	–	–	–	–	–
FCA-4653	Zoe	28.5	7.4	18.6	2,046	15,996	0	9.4	6.9	0.1	Neg/neg	Neg
FCA-4654	Thkitten	–	–	–	–	–	–	–	–	–	–	–
FCA-4655	Penny	7	4.62	6.6	2,178	4,158	0	–	–	–	–	–
FCA-4656	Basil	–	–	–	–	–	–	–	–	–	–	–
FCA-4657	Parsley	–	–	–	–	–	–	–	–	–	–	–
FCA-4658	FCAC	–	–	–	–	–	–	–	–	–	–	–
FCA-4659	Concerta	–	–	–	–	–	–	–	–	–	–	–
FCA-4660	Starfox	–	–	–	–	–	–	–	–	–	–	–
FCA-4662	OJ male	–	–	–	–	–	–	–	–	–	–	–
FCA-4663	OJ female	–	–	–	–	–	–	–	–	–	–	–
FCA-4664	Buster	–	–	–	–	–	–	–	–	–	–	–

\*ID, identification number; hem, hematocrit (%); RBC, red blood cells; WBC, white blood cells; lymph, lymphocytes; neut, neutrophils segmented; bands, neutrophils bands; pro, total protein (g/dL); Glo, globulin (g/dL); Bil, total bilirubin (mg/dL); Toxo, *Toxoplasma gondii*; FeLV, feline leukemia virus; FIV, feline immunodeficiency virus; –, not done; neg, negative; qns, quantity of sample was insufficient for test; pos, positive; FCAC, Frederick County Animal Shelter. Gray shading represents feline infectious peritonitis virus cases.